Literature DB >> 23850736

3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies.

Daniel Mueller1, Lisa Krämer, Esther Hoffmann, Sebastian Klein, Fozia Noor.   

Abstract

Predictive in vitro models alternative to in vivo animal will have a significant impact in toxicology. Conventional 2D models do not reflect the complexity of a 3D organ resulting in discrepancies between experimental in vitro and in vivo data. Using 3D HepaRG organotypic cultures we tested four drugs (aflatoxin B1, amiodarone, valproic acid and chlorpromazine) for toxic effects and compared the results with 2D HepaRG and HepG2 cultures. We show that 3D HepaRG cultures are more sensitive than the other tested cultures to aflatoxin B1 which is only toxic upon metabolic activation in the liver. We observed that CYP3A4 activity is higher in the 3D HepaRG cultures compared to the 2D HepaRG cultures. Furthermore, we investigated repeated dose toxicity of chlorpromazine and assessed its effects on glucose and lactate metabolism. Sub-toxic concentrations of chlorpromazine induced significant metabolic changes in both 2D and 3D HepaRG cultures upon acute and repeated dose (3 doses) exposure. In summary, our data support the hypothesis that 3D cell culture models better mimic the in vivo tissue and improve cellular functionality. The 3D HepaRG organotypic cultures represent a high throughput system for drug toxicity screening. This system is therefore a promising tool in preclinical testing of human relevance which can allow reducing and/or replacing animal testing for drug adverse effects.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic toxicity; HepaRG; In vitro models; Organotypic cultures; Repeated dose toxicity

Mesh:

Substances:

Year:  2013        PMID: 23850736     DOI: 10.1016/j.tiv.2013.06.024

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  43 in total

1.  From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening.

Authors:  Sreenivasa C Ramaiahgari; Suramya Waidyanatha; Darlene Dixon; Michael J DeVito; Richard S Paules; Stephen S Ferguson
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

2.  A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device.

Authors:  Jonas Christoffersson; Florian Meier; Henning Kempf; Kristin Schwanke; Michelle Coffee; Mario Beilmann; Robert Zweigerdt; Carl-Fredrik Mandenius
Journal:  Bioengineering (Basel)       Date:  2018-05-04

3.  Cell presses.

Authors:  Gunjan Sinha
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

4.  Evaluation of CdTe/CdS/ZnS core/shell/shell quantum dot toxicity on three-dimensional spheroid cultures.

Authors:  Mehriban Ulusoy; Antonina Lavrentieva; Johanna-Gabriela Walter; Franziska Sambale; Mark Green; Frank Stahl; Thomas Scheper
Journal:  Toxicol Res (Camb)       Date:  2015-08-07       Impact factor: 3.524

5.  A novel lab-on-a-chip platform for spheroid metabolism monitoring.

Authors:  Frank Alexander; Sebastian Eggert; Joachim Wiest
Journal:  Cytotechnology       Date:  2017-10-14       Impact factor: 2.058

6.  High-content imaging assays on a miniaturized 3D cell culture platform.

Authors:  Pranav Joshi; Akshata Datar; Kyeong-Nam Yu; Soo-Yeon Kang; Moo-Yeal Lee
Journal:  Toxicol In Vitro       Date:  2018-03-06       Impact factor: 3.500

7.  Neurovascular Organotypic Culture Models Using Induced Pluripotent Stem Cells to Assess Adverse Chemical Exposure Outcomes.

Authors:  Eric H Nguyen; Micah J Dombroe; Debra L Fisk; William T Daly; Christine M Sorenson; William L Murphy; Nader Sheibani
Journal:  Appl In Vitro Toxicol       Date:  2019-06-17

Review 8.  Tissue-engineered kidney disease models.

Authors:  Teresa M Desrochers; Erica Palma; David L Kaplan
Journal:  Adv Drug Deliv Rev       Date:  2013-12-17       Impact factor: 15.470

9.  Intersection of toxicogenomics and high throughput screening in the Tox21 program: an NIEHS perspective.

Authors:  B Alex Merrick; Richard S Paules; Raymond R Tice
Journal:  Int J Biotechnol       Date:  2015

Review 10.  A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.

Authors:  Fozia Noor
Journal:  J Physiol       Date:  2015-11-04       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.